HC Wainwright Brokers Increase Earnings Estimates for UNCY

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Analysts at HC Wainwright increased their FY2024 EPS estimates for shares of Unicycive Therapeutics in a research report issued on Thursday, November 14th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings per share of ($0.11) for the year, up from their previous forecast of ($0.12). HC Wainwright has a “Buy” rating and a $2.50 price target on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ FY2025 earnings at ($0.34) EPS, FY2026 earnings at ($0.22) EPS, FY2027 earnings at $0.02 EPS and FY2028 earnings at $0.53 EPS.

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 price target on shares of Unicycive Therapeutics in a research note on Friday, September 6th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $5.13.

Unicycive Therapeutics Price Performance

UNCY stock opened at $0.46 on Monday. The company has a market capitalization of $47.24 million, a PE ratio of -0.47 and a beta of 2.29. Unicycive Therapeutics has a 12 month low of $0.20 and a 12 month high of $1.82. The firm’s 50-day moving average is $0.43 and its 200 day moving average is $0.54.

Institutional Trading of Unicycive Therapeutics

Institutional investors have recently modified their holdings of the company. Bleakley Financial Group LLC bought a new stake in shares of Unicycive Therapeutics in the 3rd quarter valued at about $33,000. Virtu Financial LLC acquired a new stake in Unicycive Therapeutics during the 1st quarter valued at approximately $36,000. BVF Inc. IL lifted its stake in Unicycive Therapeutics by 70.5% during the 1st quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock valued at $4,984,000 after acquiring an additional 1,493,462 shares during the period. XTX Topco Ltd purchased a new position in shares of Unicycive Therapeutics during the 3rd quarter valued at approximately $29,000. Finally, Walleye Capital LLC purchased a new position in shares of Unicycive Therapeutics during the 3rd quarter valued at approximately $2,040,000. 40.42% of the stock is currently owned by institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.